Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study

HG. Nüßlein, R. Alten, M. Galeazzi, HM. Lorenz, MT. Nurmohamed, WG. Bensen, GR. Burmester, HH. Peter, P. Peichl, K. Pavelka, M. Chartier, C. Poncet, C. Rauch, M. Le Bars,

. 2016 ; 34 (3) : 489-99. [pub] 20160310

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027595

OBJECTIVES: To evaluate retention of abatacept over 24 months in patients with rheumatoid arthritis (RA) in routine clinical practice across Europe and Canada. METHODS: ACTION (AbataCepT In rOutiNe clinical practice) was a prospective, observational, multicentre study of adult patients with moderate-to-severe RA who, at their physician's discretion, initiated treatment with intravenous abatacept. Enrolment occurred from May 2008 to December 2010, with up to 30 months of follow-up. The primary endpoint was the abatacept retention rate over 24 months. Crude abatacept retention rate was estimated using the Kaplan-Meier method. Prognostic factors of abatacept retention in patients with ≥1 prior biologic failure were derived from a Cox proportional hazards regression model, accounting for clustered data. RESULTS: A total of 1137 patients were enrolled (1573 patient-years on abatacept); most (89.2%) had experienced prior biologic failure. The overall crude abatacept retention rate at 24 months was 54.4% (95% confidence interval: 51.3, 57.4). Positivity for both rheumatoid factor and anti-cyclic citrullinated antibody, previous exposure to one or no anti-tumour necrosis factor agents, and cardiovascular comorbidity were prognostic of higher abatacept retention. Erythrocyte sedimentation rate ≥51 mm/hour and introduction of corticosteroid use at abatacept initiation were predictors of lower abatacept retention. Abatacept retention varied according to country. Abatacept was well tolerated without any unexpected safety signals. CONCLUSIONS: In a real-world setting, intravenous abatacept treatment retention was more than 50% at 24 months. The identification of prognostic factors of abatacept retention could support individualised biologic treatment strategies in patients with moderate-to-severe RA.

000      
00000naa a2200000 a 4500
001      
bmc16027595
003      
CZ-PrNML
005      
20181022105047.0
007      
ta
008      
161005s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)26966919
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Nüßlein, Hubert G $u Rheumatologische Schwerpunktpraxis, University of Erlangen-Nuremberg, Germany. nuesslein.hu@googlemail.com.
245    10
$a Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study / $c HG. Nüßlein, R. Alten, M. Galeazzi, HM. Lorenz, MT. Nurmohamed, WG. Bensen, GR. Burmester, HH. Peter, P. Peichl, K. Pavelka, M. Chartier, C. Poncet, C. Rauch, M. Le Bars,
520    9_
$a OBJECTIVES: To evaluate retention of abatacept over 24 months in patients with rheumatoid arthritis (RA) in routine clinical practice across Europe and Canada. METHODS: ACTION (AbataCepT In rOutiNe clinical practice) was a prospective, observational, multicentre study of adult patients with moderate-to-severe RA who, at their physician's discretion, initiated treatment with intravenous abatacept. Enrolment occurred from May 2008 to December 2010, with up to 30 months of follow-up. The primary endpoint was the abatacept retention rate over 24 months. Crude abatacept retention rate was estimated using the Kaplan-Meier method. Prognostic factors of abatacept retention in patients with ≥1 prior biologic failure were derived from a Cox proportional hazards regression model, accounting for clustered data. RESULTS: A total of 1137 patients were enrolled (1573 patient-years on abatacept); most (89.2%) had experienced prior biologic failure. The overall crude abatacept retention rate at 24 months was 54.4% (95% confidence interval: 51.3, 57.4). Positivity for both rheumatoid factor and anti-cyclic citrullinated antibody, previous exposure to one or no anti-tumour necrosis factor agents, and cardiovascular comorbidity were prognostic of higher abatacept retention. Erythrocyte sedimentation rate ≥51 mm/hour and introduction of corticosteroid use at abatacept initiation were predictors of lower abatacept retention. Abatacept retention varied according to country. Abatacept was well tolerated without any unexpected safety signals. CONCLUSIONS: In a real-world setting, intravenous abatacept treatment retention was more than 50% at 24 months. The identification of prognostic factors of abatacept retention could support individualised biologic treatment strategies in patients with moderate-to-severe RA.
650    12
$a abatacept $x aplikace a dávkování $x škodlivé účinky $7 D000069594
650    _2
$a intravenózní podání $7 D061605
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a revmatoidní artritida $x diagnóza $x farmakoterapie $7 D001172
650    _2
$a krevní sedimentace $x účinky léků $7 D001799
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x aplikace a dávkování $x škodlivé účinky $7 D007166
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a posouzení stavu pacienta $7 D062072
650    _2
$a prognóza $7 D011379
650    _2
$a revmatoidní faktor $x krev $7 D012217
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Alten, Rieke $u Schlosspark-Klinik University Medicine, Berlin, Germany. $7 gn_A_00004908
700    1_
$a Galeazzi, Mauro $u University of Siena, Italy.
700    1_
$a Lorenz, Hanns-Martin $u University Hospital, Heidelberg, Germany.
700    1_
$a Nurmohamed, Michael T $u VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, The Netherlands.
700    1_
$a Bensen, William G $u St. Josephs Hospital and McMaster University, Hamilton, Canada.
700    1_
$a Burmester, Gerd R $u Charité-Universitätsmedizin, Berlin, Germany.
700    1_
$a Peter, Hans-Hartmut $u University of Freiburg, Germany.
700    1_
$a Peichl, Petr, $u Evangelisches Krankenhaus, Vienna, Austria. $d 1976- $7 xx0092197
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Chartier, Mélanie $u Chiltern International, Neuilly, France.
700    1_
$a Poncet, Coralie $u Docs International, Nanterre, France.
700    1_
$a Rauch, Christiane $u Bristol-Myers Squibb, Munich, Germany.
700    1_
$a Le Bars, Manuela $u Bristol-Myers Squibb, Rueil-Malmaison, France.
773    0_
$w MED00001116 $t Clinical and experimental rheumatology $x 0392-856X $g Roč. 34, č. 3 (2016), s. 489-99
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26966919 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20181022105553 $b ABA008
999    __
$a ok $b bmc $g 1165909 $s 952225
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 $c 3 $d 489-99 $e 20160310 $i 0392-856X $m Clinical and Experimental Rheumatology $n Clin Exp Rheumatol $x MED00001116
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace